Hims & Hers
The Business of GLP-1s: Inside the New Weight Loss Drug Ecosystem
As GLP-1 drugs surge, here's how telehealth companies and brick-and-mortar fitness giants are responding to the Ozempic era.
JP Morgan Targets Weight Loss Drugs With $500M Fund
JP Morgan Private Capital has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space.
Hims & Hers, Nestle Enter the GLP-1 Race
Hims & Hers will now provide access to compounded GLP-1s for eligible consumers at a discounted rate compared to brand-name prescriptions.
Hims Enters Weight Loss Market, but CEO Not Sold on Ozempic
Hims' new platform will roll out just in time for New Year’s resolutions, but will lean on generic medications instead of highly popular GLP-1s.
Define Ventures Raises $460 Million To Invest in Digital Health Startups
The new funding allows Define Ventures to continue its track record of investing in promising early-stage digital health startups.
Allermi Secures $3.5M for Nasal Spray; CEO Touts Benefits of Customized Allergy Relief
Allermi offers a customized, all-in-one nasal spray designed to offer relief to all types of allergy sufferers.
Hims & Hers Head to Amazon
Hims & Hers products on Amazon will include biotin, immunity & sleep gummies, collagen powder supplements, sexual health & wellness products..
